Investment Analysts’ Weekly Ratings Changes for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (NASDAQ: JAZZ) has recently received a number of price target changes and ratings updates:

  • 12/3/2019 – Jazz Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $186.00 price target on the stock, up previously from $168.00.
  • 12/2/2019 – Jazz Pharmaceuticals had its price target raised by analysts at Barclays PLC from $182.00 to $200.00. They now have an “overweight” rating on the stock.
  • 11/29/2019 – Jazz Pharmaceuticals was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating.
  • 11/27/2019 – Jazz Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/20/2019 – Jazz Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 11/13/2019 – Jazz Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 11/11/2019 – Jazz Pharmaceuticals had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $147.00 price target on the stock.
  • 11/11/2019 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by analysts at Evercore ISI.
  • 11/7/2019 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by analysts at Barclays PLC. They now have a $182.00 price target on the stock.
  • 10/18/2019 – Jazz Pharmaceuticals was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating.
  • 10/14/2019 – Jazz Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $150.00 price target on the stock.
  • 10/11/2019 – Jazz Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.

NASDAQ:JAZZ traded down $4.14 during trading hours on Tuesday, reaching $146.24. 29,304 shares of the stock were exchanged, compared to its average volume of 610,144. Jazz Pharmaceuticals PLC has a 52 week low of $113.52 and a 52 week high of $154.44. The company has a quick ratio of 3.71, a current ratio of 3.89 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $8.55 billion, a P/E ratio of 11.95, a P/E/G ratio of 1.18 and a beta of 1.15. The firm has a 50 day simple moving average of $132.43 and a 200-day simple moving average of $132.84.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.19 by $0.91. The business had revenue of $537.70 million for the quarter, compared to analyst estimates of $523.92 million. Jazz Pharmaceuticals had a return on equity of 27.99% and a net margin of 29.61%. The business’s revenue was up 14.6% compared to the same quarter last year. During the same period in the prior year, the company posted $3.58 EPS. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 14.15 earnings per share for the current year.

In other news, CEO Bruce C. Cozadd sold 500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total transaction of $65,000.00. Following the sale, the chief executive officer now owns 311,855 shares of the company’s stock, valued at $40,541,150. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 4.30% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in JAZZ. Charles Schwab Investment Management Inc. increased its position in shares of Jazz Pharmaceuticals by 2.2% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 457,226 shares of the specialty pharmaceutical company’s stock valued at $65,183,000 after purchasing an additional 9,797 shares during the period. HBK Sorce Advisory LLC bought a new position in Jazz Pharmaceuticals during the second quarter valued at about $324,000. Chicago Equity Partners LLC boosted its stake in Jazz Pharmaceuticals by 152.4% during the second quarter. Chicago Equity Partners LLC now owns 16,760 shares of the specialty pharmaceutical company’s stock valued at $2,389,000 after buying an additional 10,120 shares in the last quarter. Wedge Capital Management L L P NC grew its holdings in Jazz Pharmaceuticals by 8.0% during the third quarter. Wedge Capital Management L L P NC now owns 276,013 shares of the specialty pharmaceutical company’s stock worth $35,368,000 after acquiring an additional 20,553 shares during the period. Finally, Condor Capital Management grew its holdings in Jazz Pharmaceuticals by 3.1% during the third quarter. Condor Capital Management now owns 10,414 shares of the specialty pharmaceutical company’s stock worth $1,334,000 after acquiring an additional 318 shares during the period. 89.10% of the stock is owned by institutional investors.

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Understanding Specialty Certificates of Deposit

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.